US health advisers vote against Novo Nordisk's weekly insulin for type 1 diabetes due to risk concerns, as Danish drugmaker aims for market introduction ...
US health advisers vote against Novo Nordisk's weekly insulin for type 1 diabetes due to risk concerns, as Danish drugmaker aims for market introduction ...